Having set itself a target to reach INR5,000 crore in revenue by 2029, Redcliffe Labs is expanding rapidly and spending big on marketing. But scaling up in a services industry like diagnostics isn’t easy. Without sufficient funding, it may not be able to tap the small-town potential it is banking on. Besides, competition and pricing pressure are intense.
Diagnostics chain Redcliffe Labs has been making quite a buzz of late. It is gearing up to take on the incumbents and make a mark in the fragmented diagnostics market in India. Started in 2018 as a company focused genetic, specialised, and rare diseases testing, Redcliffe Labs ventured into infectious diseases, including Covid-19 testing in 2020 and expanded to a full-stack testing menu of routine and specialised pathology tests as well as
Refer & Earn
Get Unlimited Access to The Economic Times
